EClinicalMedicine, Год журнала: 2023, Номер 67, С. 102374 - 102374
Опубликована: Дек. 13, 2023
The pivotal phase 3 efficacy clinical trial has demonstrated that a two-dose regimen of dNS1-RBD (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) is well-tolerated and provides wide protection against SARS-CoV-2 infection. However, the effectiveness single-dose still unknown. We aimed to estimate one-dose symptomatic Omicron infections in real-world conditions.
Язык: Английский
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Янв. 4, 2024
Abstract The global rollout of COVID-19 vaccines faces a significant barrier in the form vaccine hesitancy. This study adopts dynamic and network perspective to explore determinants uptake Hong Kong, focusing on multi-level their interconnections. Following framework proposed by Strategic Advisory Group Experts (SAGE), used repeated cross-sectional surveys map these at multiple levels investigates interconnections simultaneously sample 15,179 over two years. results highlight nature hesitancy an evolving pandemic. findings suggest that confidence attitudes play crucial roles vaccination uptake, with importance shifting time. initial emphasis safety gradually transitioned heightened consideration effectiveness later stage. also highlights impact chronic condition, age, case numbers, non-pharmaceutical preventive behaviours uptake. Higher educational attainment being married were associated primary booster it may be possible leverage groups as early innovation adopters. Trust government acts bridging factor linking various variables networks attitudes, which subsequently closely linked provides insights for designing future effective programmes changing circumstances.
Язык: Английский
Процитировано
12
Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)
Опубликована: Фев. 18, 2024
Our study aims to assess the public's perceptions of respiratory syncytial virus (RSV) and attitudes toward RSV vaccine identify associated factors in China. A nationwide cross-sectional survey conducted using an online platform between August 16 September 14, 2023. Questions related socio-demographics, awareness, knowledge, susceptibility severity RSV, were included questionnaire. We used chi-square test logistic regression model explore factors. Overall, 2133 individuals this study. Nearly a quarter participants (24.3%) indicated that they had never heard RSV. The proportion aged over 50 years reporting having (36.5%) low knowledge level (55.3%) was significantly higher other younger age groups. More than half (55.7%) exhibited concerning infection. total 68.4% expressed willingness receive vaccine. Younger positively with be vaccinated. most frequent reason for declining "Concern about vaccine's safety or side effects." About 60% considered price below 200 CNY (28 USD) as acceptable. awareness perceived infection limited Chinese public. It is necessary take measures address acceptability among older adults.
Язык: Английский
Процитировано
10
Vacunas, Год журнала: 2025, Номер 26(1), С. 100384 - 100384
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1
Vaccine, Год журнала: 2024, Номер 42(17), С. 3684 - 3692
Опубликована: Май 6, 2024
Trust in governments and public institutions as a determinant of health outcomes has gained increased attention since the COVID-19 pandemic. Provided historically low confidence vaccines Japan, investigating role trust information sources actual vaccination uptake behavior will be invaluable for future vaccine promotion policymaking. Therefore, objective this study was to elucidate determinants evaluate relationship between different Japan. For study, we leveraged longitudinal series web-based surveys 19,174 individuals Japan conducted 2021 2022 which asked questions regarding wide range sociodemographic psychographic characteristics related Determinant analysis (at least one dose vaccine) via multiple logistic regression, odds ratios (OR) with 95% intervals (CI) were estimated. After adjustment uptake, aggregate systems approval (OR: 1.42, CI: 1.30–1.56), about pandemic coming from government 1.27, 1.12–1.44) found consistently powerful predictors vaccination. media including traditional 1.21, 1.07–1.36), internet 0.77, 0.66–0.89) had significant opposing effects. Our findings support broader hypothesis that remains We also decision-making is multifactorial process includes synthesis media, its interaction psychosocial such prosociality literacy. hope apply study's towards programs contagious diseases.
Язык: Английский
Процитировано
7
Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)
Опубликована: Май 13, 2024
Abstract The safety and efficacy of COVID-19 vaccines in the elderly, a high-risk group for severe infection, have not been fully understood. To clarify these issues, this prospective study followed up 157 elderly 73 young participants 16 months compared safety, immunogenicity, two doses inactivated vaccine BBIBP-CorV by booster dose recombinant protein ZF2001. results showed that vaccination protocol was safe tolerable elderly. After administering BBIBP-CorV, positivity rates titers neutralizing anti-RBD antibodies were significantly lower than those individuals. ZF2001 dose, antibody-positive comparable to young; however, antibody remained lower. Gender, age, underlying diseases independently associated with immunogenicity pseudovirus neutralization assay that, after receiving priming, some obtained immunological protection against BA.5 BF.7 booster. Breakthrough infection symptoms last longer infected pre-infection negatively severity post-infection symptoms. levels increased breakthrough but still young. Our data suggest multiple vaccinations at short intervals maintain high may be an effective strategy protecting COVID-19.
Язык: Английский
Процитировано
6
Journal of Medical Virology, Год журнала: 2024, Номер 96(7)
Опубликована: Июль 1, 2024
Globally, the rollout of COVID-19 vaccine had been faced with a significant barrier in form hesitancy. This study adopts multi-stage perspective to explore prevalence and determinants hesitancy, focusing on their dynamic evolutionary features. Guided by integrated framework 3Cs model (complacency, confidence, convenience) EAH (environmental, agent, host), this conducted three repeated national cross-sectional surveys. These surveys carried out from July 2021 February 2023 across mainland China, targeted individuals aged 18 older. They were strategically timed coincide critical vaccination phases: universal coverage (stage 1), partial 2), key population 3). From 2023, examined sample sizes 29 925, 6659, 5407, respectively. The hesitation rates increased 8.39% 29.72% 2023. Urban residency, chronic condition, low trust developer contributed hesitancy pandemic. Negative correlations between intensity policies positive long COVID, confirmed. provides insights for designing future effective programs emerging vaccine-preventable infectious X diseases.
Язык: Английский
Процитировано
6
Cureus, Год журнала: 2024, Номер unknown
Опубликована: Янв. 18, 2024
Introduction: COVID-19 has become a burden to all nations across the globe, and vaccination currently remains most effective means of fighting SARS-COV-2 pandemic. From time approval subsequent distribution various vaccines, nearly 72.3% (5.5 billion) globe's population have been vaccinated, leaving slightly more than quarter at risk. With availability booster vaccine dosages individuals with chronic conditions, including coronary heart disease (CHD), it is vital comprehend factors underlying uptake in such subgroups. Further, American Heart Association recommends against populations (CHD). This because they are likely experience severe outcomes due infection. study assesses vaccines as well predictors its uptake. Methods: Using 2022 survey data from National Health Interview Survey (NHIS), 1,708 adults ≥ 40 years CHD who responded yes/no whether had received were identified. A Pearson's chi-square test was used ascertain differences among those not. logistic regression (multivariate regression) evaluate vaccination. Results: About 1,491/1,708 (86.8%) reported being vaccinated COVID-19. Among them, 1,065/1,491 (68.4%) two doses. The older age (odds ratio (OR): 2.01 (95% confidence interval (CI): 1.40-2.89), p < 0.001), family income poverty threshold 1 above (OR: 2.40 CI: 1.58-3.64), having college degree 3.09 1.85-5.14), insured 3.26 1.03-10.26), = 0.044). Conclusion: findings indicated that 68.4% doses vaccines. More half followed recommendations vaccine. Old (above years) higher socioeconomic class associated follow guidelines. Despite rate diseases group, strategies for improving awareness alongside accessibility needed enhance additional dosage uptake, protect them novel variants, ensure development sustained immunity.
Язык: Английский
Процитировано
5
Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)
Опубликована: Июнь 5, 2024
Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes (HZ) in healthy ≥ 50-year-olds, with a efficacy (VE) > 90% across age groups. These pivotal trials did not enroll participants from mainland China where RZV is licensed, therefore similar clinical data are missing for this population. In phase IV observer-blind study (NCT04869982) conducted between 2021 2023 China, immunocompetent medically stable 50-year-olds were randomized 1:1 to receive two or placebo doses, 2 months apart. This assessed VE (overall, as confirmatory objective, descriptively by category [50–69-year-olds/≥ 70-year-olds]), reactogenicity, safety of Chinese Of 6138 enrolled participants, 99.2% completed study. During mean follow-up period 15.2 (±1.1) months, 31 HZ episodes confirmed (RZV = 0; 31) an incidence rate 0.0 vs 8.2 per 1000 person-years overall 100% (89.82–100). The descriptive (85.29–100) 50–69-year-olds (60.90–100) 70-year-olds. Solicited adverse events (AEs) more frequent group (median duration: 1–3 days both groups). Pain fatigue most local general AEs (RZV: 72.1% 43.4%; placebo: 9.2% 5.3%). frequencies unsolicited AEs, serious potential immune-mediated diseases, deaths efficacious preventing consistent including worldwide populations medical characteristics.
Язык: Английский
Процитировано
5
BMC Public Health, Год журнала: 2025, Номер 25(1)
Опубликована: Фев. 7, 2025
Although the second booster dose of COVID-19 vaccines is available, vaccine hesitancy among public may have peaked due to surge in infections caused by Omicron variant. To improve coverage dose, it crucial investigate prevalence general population during this period and explore reasons for phenomenon. A cross-sectional survey was conducted between January 5 February 9, 2023. Variables including sociodemographics, mental health, infection status, vaccination were collected. Univariate multivariate logistic regression analysis performed identify factors associated with population. Among 10,623 participants, uptake rate 4.3%. those who did not receive 43.6% expressed hesitancy. The highest observed participants had completed primary immunization (71.4%), followed chronic diseases (48.6%) aged 60 above (33.2%). higher females, high incomes, a history infection, depressive symptoms post-traumatic stress disorder, adverse events after vaccination. Conversely, lower students, above, from southern China, level perceived social support. remains prevalent China pandemic. Crucial steps, such as raising awareness benefits potential side effects regular vaccination, ensuring timely monitoring disclosure pandemic information, implementing targeted measures support should be taken. These efforts will instrumental reducing hesitancy, advancing campaigns, effectively preparing future outbreaks.
Язык: Английский
Процитировано
0
npj Digital Medicine, Год журнала: 2023, Номер 6(1)
Опубликована: Май 25, 2023
Chatbots have become an increasingly popular tool in the field of health services and communications. Despite chatbots' significance amid COVID-19 pandemic, few studies performed a rigorous evaluation effectiveness chatbots improving vaccine confidence acceptance. In Thailand, Hong Kong, Singapore, from February 11th to June 30th, 2022, we conducted multisite randomised controlled trials (RCT) on 2,045 adult guardians children seniors who were unvaccinated or had delayed vaccinations. After week using chatbots, differences acceptance compared between intervention control groups. Compared non-users, fewer chatbot users reported decreased Thailand child group [Intervention: 4.3 % vs. Control: 17%, P = 0.023]. However, more [26% 12%, 0.028] Kong safety [29% 10%, 0.041] Singapore group. There was no statistically significant change senior Employing RE-AIM framework, process indicated strong implementation support for stakeholders, with high levels sustainability scalability. This multisite, parallel RCT study found mixed success among Asian subpopulations. Further that link usage real-world uptake are needed augment evidence employing advance
Язык: Английский
Процитировано
12